Drug firm Lupin today posted an increase of 42.57% in its consolidated net profit to Rs 335.2 crore for the third quarter ended December 31, 2012, on the back of strong sales in the US market.
The Mumbai-headquartered firm had posted a net profit of Rs 235.1 crore during the same period of previous fiscal.
Consolidated net sales of the company rose by 37.62% to Rs 2,465.9 crore during the third quarter, as against Rs 1,791.7 crore during the same period of 2011-12 fiscal, Lupin Ltd said in a statement.
"We had a record quarter driven by strong operating performance and growth in the US. Importantly, we continue to improve on margins consistently," Lupin Ltd Managing Director Kamal K Sharma said.
Shares of Lupin were trading at Rs 608.15 apiece on the BSE in late afternoon trade, up 1.49% from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app